These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

529 related items for PubMed ID: 22812645

  • 1. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M.
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [Abstract] [Full Text] [Related]

  • 2. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
    Moon DG, Park MG, Lee SW, Park K, Park JK, Kim SW, Park NC, Ahn TY, Paick JS, Seo JT, Yang DY, Lee JY, Kim JJ.
    J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
    [Abstract] [Full Text] [Related]

  • 3. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
    Permpongkosol S, Tantirangsee N, Ratana-olarn K.
    J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
    [Abstract] [Full Text] [Related]

  • 4. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
    Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, Saghir A, Blast Study Group.
    Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
    [Abstract] [Full Text] [Related]

  • 5. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S, Khupulsup K, Leelaphiwat S, Pavavattananusorn S, Thongpradit S, Petchthong T.
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [Abstract] [Full Text] [Related]

  • 6. Testosterone undecanoate in the treatment of male hypogonadism.
    Edelstein D, Basaria S.
    Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
    [Abstract] [Full Text] [Related]

  • 7. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
    Yassin DJ, Doros G, Hammerer PG, Yassin AA.
    J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
    [Abstract] [Full Text] [Related]

  • 8. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
    Zitzmann M, Nieschlag E.
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
    [Abstract] [Full Text] [Related]

  • 9. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ.
    J Androl; 1998 Oct; 19(6):761-8. PubMed ID: 9876028
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
    Wang C, Harnett M, Dobs AS, Swerdloff RS.
    J Androl; 2010 Oct; 31(5):457-65. PubMed ID: 20133964
    [Abstract] [Full Text] [Related]

  • 11. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
    Giagulli VA, Triggiani V, Carbone MD, Corona G, Tafaro E, Licchelli B, Guastamacchia E.
    J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
    [Abstract] [Full Text] [Related]

  • 12. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF, Reid M, Madden W, Burnett AL.
    Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
    [Abstract] [Full Text] [Related]

  • 13. Injectable testosterone undecanoate for the treatment of hypogonadism.
    Corona G, Maseroli E, Maggi M.
    Expert Opin Pharmacother; 2014 Sep; 15(13):1903-26. PubMed ID: 25080279
    [Abstract] [Full Text] [Related]

  • 14. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M, Minnemann T, Hübler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F.
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [Abstract] [Full Text] [Related]

  • 15. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
    Minnemann T, Schubert M, Freude S, Hübler D, Gouni-Berthold I, Schumann C, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F.
    J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
    [Abstract] [Full Text] [Related]

  • 16. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
    Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P.
    J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
    [Abstract] [Full Text] [Related]

  • 17. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men.
    Jockenhövel F, Minnemann T, Schubert M, Freude S, Hübler D, Schumann C, Christoph A, Ernst M.
    Eur J Endocrinol; 2009 May; 160(5):815-9. PubMed ID: 19225035
    [Abstract] [Full Text] [Related]

  • 18. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only.
    Yassin AA, Saad F.
    J Sex Med; 2007 Mar; 4(2):497-501. PubMed ID: 17367445
    [Abstract] [Full Text] [Related]

  • 19. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
    Hackett G, Cole N, Saghir A, Jones P, Strange RC, Ramachandran S.
    BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and tolerability of parenteral testosterone undecanoate: a post-marketing surveillance study.
    Wolf J, Keipert D, Motazedi H, Ernst M, Nettleship J, Gooren L.
    Aging Male; 2017 Dec; 20(4):225-234. PubMed ID: 28812471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.